Medication Description: Erythrophosphatid (Erytrophosphatidum)
A drug derived from human erythrocytes. Contains glycerophospholipids: phosphatidylcholine, phosphatidylethanolamine, phosphatidylserine, phosphatidylmielin.
Yellowish opalescent emulsion; pH 5, 5 - 6, 8.
Glycerophospholipids play an important role in the life processes of the body; being components of biological membranes, they affect their permeability, participate in the transmission of nerve impulses, in energy processes.
As a medicine, erythrophosphatid is used as a hemostatic, hemostimulating and desensitizing agent.
Used in adults with hemorrhagic diathesis associated with impaired thrombus formation, Verlgof's disease, hypo- and aplastic anemias, leukemia, etc., for coagulation disorders caused by insufficiency of factors VIII, IX, V, VII and others. At the same time, appropriate hemocoagulating factors can be used facilities.
As an antianemic agent, erythrophosphatid is prescribed for the complex treatment of chronic post-hemorrhagic, iron-deficient, hypoplastic and other anemias.
As a desensitizing agent, the drug is used for diseases accompanied by auto-and iso-sensitization phenomena.
Apply erythrophosphatid intramuscularly.
To enhance blood coagulation injected (adults) 150 to 300 mg in 1 to 2 days. The maximum effect is observed 2 to 3 hours after intramuscular administration. If necessary, injections are performed 2 to 3 times a day for 2 to 3 days or more. The daily dose is 750 mg.
With anemia, erythrophosphatid is administered in 150 mg 1 time every 4 to 5 days, a total of 10 to 15 injections. In case of anemia with a pronounced violation of bone marrow hematopoiesis, the course dose of the drug can be increased to 30 - 50 injections.
In the case of severe acute or chronic hypoxia due to deep anemia, when a patient needs blood transfusion, and blood transfusions cause sensitization, erythrophosphamide is administered intramuscularly 1–2 hours before a blood transfusion for desensitization.
The drug is contraindicated in case of increased blood clotting.
Form release: in ampoules containing 5 ml of the drug (emulsion), in a package of 10 ampoules.
Storage: at a temperature of + 4 to + 8'C protected from light.